These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29788331)

  • 1. Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
    Garcia-Prats AJ; Draper HR; Finlayson H; Winckler J; Burger A; Fourie B; Thee S; Hesseling AC; Schaaf HS
    Clin Infect Dis; 2018 Nov; 67(11):1777-1780. PubMed ID: 29788331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
    Thee S; Garcia-Prats AJ; McIlleron HM; Wiesner L; Castel S; Norman J; Draper HR; van der Merwe PL; Hesseling AC; Schaaf HS
    Antimicrob Agents Chemother; 2014 May; 58(5):2948-51. PubMed ID: 24550337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
    Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
    Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
    Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis.
    Adler-Shohet FC; Low J; Carson M; Girma H; Singh J
    Pediatr Infect Dis J; 2014 Jun; 33(6):664-6. PubMed ID: 24445837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
    von Gottberg A; Klugman KP; Cohen C; Wolter N; de Gouveia L; du Plessis M; Mpembe R; Quan V; Whitelaw A; Hoffmann R; Govender N; Meiring S; Smith AM; Schrag S;
    Lancet; 2008 Mar; 371(9618):1108-13. PubMed ID: 18359074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH; Xu HB; Li L
    Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
    Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
    Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin.
    Huguet A; Ader F; Ohlmann C; Collardeau-Frachon S; Gillet Y
    Pediatr Infect Dis J; 2019 Oct; 38(10):1025-1026. PubMed ID: 31335574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
    Malik AA; Brooks MB; Siddiqui S; Fuad J; Peloquin CA; Amanullah F; Jaswal M; Becerra MC; Hussain H; Yuen CM
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.
    Seddon JA; Hesseling AC; Finlayson H; Fielding K; Cox H; Hughes J; Godfrey-Faussett P; Schaaf HS
    Clin Infect Dis; 2013 Dec; 57(12):1676-84. PubMed ID: 24065321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
    Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
    Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
    Papastavros T; Dolovich LR; Holbrook A; Whitehead L; Loeb M
    CMAJ; 2002 Jul; 167(2):131-6. PubMed ID: 12160118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis.
    Qiujing F; Weiwei W
    Pak J Pharm Sci; 2020 May; 33(3(Special)):1361-1366. PubMed ID: 33361023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
    Kempker RR; Barth AB; Vashakidze S; Nikolaishvili K; Sabulua I; Tukvadze N; Bablishvili N; Gogishvili S; Singh RS; Guarner J; Derendorf H; Peloquin CA; Blumberg HM
    Antimicrob Agents Chemother; 2015; 59(6):3149-55. PubMed ID: 25779583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.